Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) insider David Krempa sold 25,000 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $65.07, for a total value of $1,626,750.00. Following the completion of the sale, the insider owned 37,025 shares in the company, valued at approximately $2,409,216.75. The trade was a 40.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
David Krempa also recently made the following trade(s):
- On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.49, for a total transaction of $1,181,630.76.
- On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.47, for a total transaction of $619,298.13.
Eton Pharmaceuticals Trading Up 1.5%
NASDAQ ETON opened at $64.43 on Tuesday. The stock has a market cap of $1.84 billion, a PE ratio of 169.55 and a beta of 0.86. Eton Pharmaceuticals, Inc. has a 12 month low of $14.27 and a 12 month high of $66.37. The company's 50-day moving average price is $42.81 and its 200-day moving average price is $30.69. The company has a current ratio of 1.52, a quick ratio of 1.30 and a debt-to-equity ratio of 0.41.
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.24. The company had revenue of $37.59 million during the quarter, compared to analyst estimates of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 40.13%. Equities research analysts forecast that Eton Pharmaceuticals, Inc. will post 0.67 earnings per share for the current year.
Institutional Trading of Eton Pharmaceuticals
Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Eton Pharmaceuticals in the 2nd quarter valued at $68,629,000. Nantahala Capital Management LLC purchased a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth $42,569,426,000. Pillsbury Lake Capital LLC bought a new stake in Eton Pharmaceuticals during the second quarter valued at about $14,015,083,000. Soleus Capital Management L.P. bought a new stake in Eton Pharmaceuticals during the second quarter valued at about $4,061,000. Finally, Millennium Management LLC boosted its position in Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company's stock valued at $4,620,000 after purchasing an additional 217,042 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on the company. Canaccord Genuity Group boosted their price target on Eton Pharmaceuticals from $60.00 to $68.00 and gave the company a "buy" rating in a report on Friday, August 14th. HC Wainwright raised their price objective on Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a "buy" rating in a report on Friday, August 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen upgraded Eton Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 13th. Finally, Craig Hallum increased their price target on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, July 28th. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $67.50.
Check Out Our Latest Analysis on Eton Pharmaceuticals
Eton Pharmaceuticals Company Profile
(
Get Free Report)
Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.
The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
